[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100660010":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":40,"studyPopulation":40,"armGroups":47,"interventions":62,"overallOfficials":75,"centralContacts":79,"locations":88,"responsibleParty":120,"collaborators":40,"id":123,"slug":124,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":125,"sex":131,"minAge":132,"maxAge":40,"enrollmentInfo":133,"targetDuration":40,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":144,"whyStopped":40,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"The University of Texas Health Science Center, Houston","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":18,"otherOutcomes":40},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Biologic aging, as measured by validated epigenetic clocks","Epigenetic age will be estimated using DNA methylation-based epigenetic clock analysis. Epigenetic age will be reported in years.","Baseline",{"measure":10,"description":11,"timeFrame":14},"Week 24",{"measure":16,"description":11,"timeFrame":17},"Change in biologic aging, as measured by validated epigenetic clocks","Baseline, week 24",[19,21,23,25,28,30,32,35,38],{"measure":20,"description":11,"timeFrame":17},"Change in epigenetic age in participants switching to DOR\u002FISL from a NRTI-sparing regimen vs. NRTI-containing regimen",{"measure":22,"description":11,"timeFrame":17},"Change in epigenetic age in participants switching to DOR\u002FISL from a NRTI-sparing regimen vs. SOC ART",{"measure":24,"description":11,"timeFrame":17},"Change in epigenetic age in participant switching to DOR\u002FISL from a NRTI-containing regimen vs. SOC ART",{"measure":26,"description":27,"timeFrame":17},"Change in pace of aging in participants switching to DOR\u002FISL from a NRTI-sparing regimen vs. NRTI-containing regimen","This will be estimated from DNA isolated from whole blood collected in a DNA\u002FRNA Shield tube using DNA methylation-based epigenetic clock analysis.",{"measure":29,"description":27,"timeFrame":17},"Change in pace of aging in participants switching to DOR\u002FISL from a NRTI-sparing regimen vs. SOC ART",{"measure":31,"description":27,"timeFrame":17},"Change in pace of aging in participants switching to DOR\u002FISL from a NRTI-containing regimen vs. SOC ART",{"measure":33,"description":27,"timeFrame":34},"Pace of aging in participants continuing SoC ART","from baseline to week 24",{"measure":36,"description":37,"timeFrame":17},"Change in epigenetic age in participants continuing SoC ART","Epigenetic age will be estimated using DNA methylation-based epigenetic clock analysis. Epigenetic age will be measured in years.",{"measure":39,"description":40,"timeFrame":34},"DOR\u002FISL tolerability as assessed by number of adverse events reported",null,{"allocation":42,"interventionModel":43,"interventionModelDescription":40,"primaryPurpose":44,"observationalModel":40,"timePerspective":40,"maskingInfo":45},"RANDOMIZED","PARALLEL","SUPPORTIVE_CARE",{"masking":46,"maskingDescription":40,"whoMasked":40},"NONE",[48,53,57],{"label":49,"type":50,"description":40,"interventionNames":51},"Group 1","EXPERIMENTAL",[52],"Drug: Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR\u002FISL",{"label":54,"type":50,"description":40,"interventionNames":55},"Group 2",[56],"Drug: Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR\u002FISL",{"label":58,"type":59,"description":40,"interventionNames":60},"Group 3","ACTIVE_COMPARATOR",[61],"Drug: Continue SoC ART",[63,68,71],{"type":64,"name":65,"description":66,"armGroupLabels":67,"otherNames":40},"DRUG","Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR\u002FISL","DOR\u002FISL (100mg\u002F0.25mg) will be supplied as coformulated tablets to be taken orally once daily.",[49],{"type":64,"name":69,"description":66,"armGroupLabels":70,"otherNames":40},"Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR\u002FISL",[54],{"type":64,"name":72,"description":73,"armGroupLabels":74,"otherNames":40},"Continue SoC ART","participants will continue to receive standard of care ART",[58],[76],{"name":77,"affiliation":5,"role":78},"Jordan E Lake, MD, MSc","PRINCIPAL_INVESTIGATOR",[80,84],{"name":77,"role":81,"phone":82,"phoneExt":40,"email":83},"CONTACT","(713) 500-6759","Jordan.E.Lake@uth.tmc.edu",{"name":85,"role":81,"phone":86,"phoneExt":40,"email":87},"Arezou S Akha","(713) 500-6500","Arezou.SadighiAkha@uth.tmc.edu",[89,107],{"facility":90,"status":40,"city":91,"state":92,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":102},"University of Colorado Anschutz Medical Center","Aurora","Colorado","80045","United States","US",{"type":97,"coordinates":98},"Point",[99,100],-104.83192,39.72943,{"lat":100,"lon":99},[103],{"name":104,"role":81,"phone":105,"phoneExt":40,"email":106},"Kristine Erlandson, MD","303-724-4941","KRISTINE.ERLANDSON@CUANSCHUTZ.EDU",{"facility":108,"status":40,"city":109,"state":110,"zip":111,"country":94,"countryCode":95,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"The University of Texas Health Science Center at Houston","Houston","Texas","77030",{"type":97,"coordinates":113},[114,115],-95.36327,29.76328,{"lat":115,"lon":114},[118,119],{"name":77,"role":81,"phone":82,"phoneExt":40,"email":83},{"name":85,"role":81,"phone":86,"phoneExt":40,"email":87},{"type":78,"investigatorFullName":121,"investigatorTitle":122,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Jordan Elizabeth Lake","Professor","100660010","phase-2-effects-of-switch-to-doravirineislatravir-vs-continued-antiretroviral-therapy-on-biomarkers-of-aging-among-virologically-suppressed-people-with-hiv-100660010",false,"NCT07871552","Effects of Switch to Doravirine\u002FIslatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV","A Pilot, Randomized, Open-Label Trial of the Effects of Switch to Doravirine\u002FIslatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV","DELILAH","Inclusion Criteria:\n\n* Living with HIV-1 and on ART for greater than or equal to 2 years (to allow for epigenetic stabilization after ART initiation\n* Current ART greater than or equal to 6 months prior to entry. ART must contain 1) FTC or 3TC with TAF or TDF or 2) any NRTI-sparing regimen consisting of greater than or equal to 2 drugs\n* HIV-1 RNA \\\u003C50 copies\u002FmL at screening and less than or equal to 200 copies\u002FmL within 6 months of entry (latter according to clinical care records). Repeat HIV-1 RNA within the screening allowed if needed to verify eligibility.\n* Able and willing to provide informed consent and undergo study procedures.\n\nExclusion Criteria:\n\n* HIV-2\n* Pregnant or nursing, or intent to become pregnant during the study period\n* Hypersensitivity or other contraindication to DOR or ISL or any of the components of the study product, as determined by the site investigator.\n* Active AIDS-defining opportunistic infection \\\u003C30 days prior to entry.\n* Active malignancy (exclusive of basal\u002Fsquamous cell skin cancer)\n* Active Hepatitis B Virus\n* Chronic Hepatitis C Virus\n* Other concomitant chronic inflammatory diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis), in the opinion of the site investigator\n* Advanced liver disease (Childs-Pugh Class B or C)\n* Any condition, therapy, laboratory abnormality or other circumstance that the site investigator feels may confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate.\n* Concomitant (current or \\\u003C45 days of entry) use of any investigational compound or device.\n* Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or strong and moderate Cytochrome P450 3A (CYP3A) inducers from \\\u003C45 days prior to entry through the study treatment period\n* Documented or known virologic resistance to DOR, as demonstrated by any of the following DOR resistance substitutions in RT: Valine106Alanine\u002FMethionine (V106A\u002FM), Valine108 Isoleucine (V108I), tyrosine 188 leucine (Y188L), Histidine 221 tyrosine (H221Y), Proline 225 histidine (P225H), Phenylalanine 227 cysteine, leucine, or valine (F227C\u002FL\u002FV), Methionine 230 isoleucine\u002Fleucine (M230I\u002FL), Leucine 2341 isoleucine (L234I), Proline 236 leucine (P236L) or Tyrosine 318 phenylalanine (Y318F)\n* Concern for risk of virologic failure with switch to DOR, based on participant history and in the opinion of the site investigator\n* Use of agents containing glucagon-like peptide-1 receptor agonists during the study or within 24 W of entry\n* Any of the following laboratory abnormalities:\n* Alkaline phosphatase (AP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>5x the upper limit of normal (ULN).\n* Calculated creatinine clearance less than or equal to 30 mL\u002Fmin, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation -Cluster of Differentiation 4 (CD4+) T cell count \\\u003C50 cells\u002Fmm3\n* Absolute lymphocyte count \\\u003C0.650 × 109 cells\u002FL\n* Hemoglobin (Hb) \\\u003C9 or \\\u003C10 g\u002FdL for persons assigned female or male sex at birth, respectively","ALL","35 Years",{"count":134,"type":135},60,"ESTIMATED","INTERVENTIONAL",[138],"PHASE2","The purpose of this study is to quantify biologic aging (using validated epigenetic clocks) as downstream indicators of Long Interspersed Nuclear Element-1 (LINE-1) retrotransposon activity before and after switch to doravirine (DOR)\u002FIslatravir (ISL) , to estimate whether effects of DOR\u002FISL on biologic aging vary by entry antiretroviral therapy (ART) regimen, and relative to continued standard of care (SoC) ART and to obtain the tolerability (adverse event profile) associated with switch to DOR\u002FISL relative to continued SoC ART",[141],"Epigenetic Aging",[143],"HIV","NOT_YET_RECRUITING","2026-10-06",{"date":147,"type":148},"2026-10-13","ACTUAL",{"date":150,"type":135},"2026-10-30",{"date":152,"type":135},"2028-10-15",{"name":5,"class":6},2]